Holen Sie sich die Stockscreener-App
37.70
1.26%
0.47
Handel nachbörslich:
37.70
Schlusskurs vom Vortag:
$37.23
Offen:
$37.23
24-Stunden-Volumen:
905.41K
Relative Volume:
0.73
Marktkapitalisierung:
$3.95B
Einnahmen:
$7.70M
Nettoeinkommen (Verlust:
$-465.32M
KGV:
-7.6245
EPS:
-4.9446
Netto-Cashflow:
$-383.68M
1W Leistung:
+10.01%
1M Leistung:
-1.39%
6M Leistung:
-9.55%
1J Leistung:
+40.20%
1-Tages-Spanne:
$36.58
$38.58
1-Wochen-Bereich:
$34.79
$38.58
52-Wochen-Spanne:
$24.10
$57.99
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Firmenname
Crinetics Pharmaceuticals Inc
Sektor
Branche
Telefon
858-450-6464
Adresse
6055 LUSK BLVD., SAN DIEGO, CA
Compare CRNX vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
37.70 | 3.90B | 7.70M | -465.32M | -383.68M | -4.9446 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-12 | Hochstufung | Goldman | Neutral → Buy |
| 2025-07-10 | Eingeleitet | Goldman | Neutral |
| 2025-03-25 | Eingeleitet | Stifel | Buy |
| 2025-02-11 | Eingeleitet | TD Cowen | Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-01-22 | Hochstufung | Jefferies | Hold → Buy |
| 2024-03-06 | Eingeleitet | Citigroup | Buy |
| 2024-01-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-12-21 | Eingeleitet | Jefferies | Hold |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-08-31 | Eingeleitet | Oppenheimer | Outperform |
| 2023-04-24 | Eingeleitet | Piper Sandler | Overweight |
| 2023-03-30 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-11-30 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-11-23 | Eingeleitet | Evercore ISI | Outperform |
| 2021-06-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-12-23 | Eingeleitet | ROTH Capital | Buy |
| 2019-02-14 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-08-13 | Eingeleitet | JP Morgan | Neutral |
| 2018-08-13 | Eingeleitet | Leerink Partners | Outperform |
| 2018-08-13 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Crinetics Pharmaceuticals Inc Aktie (CRNX) Neueste Nachrichten
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B - MSN
Aberdeen Group plc Buys 334,584 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Price performance - Yahoo Finance Australia
Crinetics Pharmaceuticals Inc (6Z4.DU) stock price, news, quote and history - Yahoo Finance UK
Price-Driven Insight from (CRNX) for Rule-Based Strategy - Stock Traders Daily
CRNX Stock Price, Quote & Chart | CRINETICS PHARMACEUTICALS IN (NASDAQ:CRNX) - ChartMill
Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More - AOL.com
Crinetics Pharmaceuticals Director Sells Shares - intellectia.ai
Crinetics Pharmaceuticals Inc. (CRNX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
CRNX PE Ratio & Valuation, Is CRNX Overvalued - Intellectia AI
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Crinetics Pharma Director Stock SaleMarch 2026 Transaction DetailsNews and Statistics - IndexBox
Crinetics Pharma COO to step down - MSN
Crinetics Pharmaceuticals (NASDAQ:CRNX) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Crinetics submits application for acromegaly drug in Brazil By Investing.com - au.investing.com
Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify (Paltusotine) in Acromegaly - Bitget
Vanguard disaggregates holdings; Crinetics (CRNX) parent reports 0 shares - Stock Titan
Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly - The Manila Times
Crinetics submits application for acromegaly drug in Brazil - Investing.com
Crinetics Pharmaceuticals Announces Submission of Marketing - globenewswire.com
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B (XLV:NYSEARCA) - Seeking Alpha
Crinetics Pharmaceuticals (CRNX) Executive Resignation Announced - GuruFocus
Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 4.3%Here's Why - MarketBeat
Crinetics Pharmaceuticals, Inc. Announces Resignation of Jeff Knight as Chief Development and Operating Officer, Effective on or About April 10, 2026 - MarketScreener
Crinetics Pharmaceuticals, Inc. Files Form 8-K with SEC: Company Details, Stock Info, and Compliance Data (March 2026) - Minichart
Crinetics Pharmaceuticals chief development and operating officer to resign By Investing.com - Investing.com South Africa
Crinetics Pharmaceuticals chief development and operating officer to resign - Investing.com
Crinetics' Jeff Knight to Resign as Chief Development and Operating Officer - TradingView
Crinetics (NASDAQ: CRNX) COO-level executive Jeff Knight to resign by April 10, 2026 - Stock Titan
Q4 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q2 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q1 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q3 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - gurufocus.com
Stock Market Recap: Is Crinetics Pharmaceuticals Inc a stock for growth or value investorsTake Profit & Daily Stock Trend Watchlist - baoquankhu1.vn
Merger Talk: Whats the beta of Crinetics Pharmaceuticals Inc stockWeekly Market Report & Technical Entry and Exit Alerts - baoquankhu1.vn
JPMorgan Chase & Co. Acquires 926,765 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
CRNX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Patterns Watch: What is the dividend yield of Crinetics Pharmaceuticals Inc2026 Retail & Weekly Top Gainers Alerts - baoquankhu1.vn
Crinetics Pharmaceuticals (NASDAQ:CRNX) Insider Stephen Betz Sells 10,612 Shares - MarketBeat
Crinetics Pharmaceuticals (NASDAQ:CRNX) CEO Sells $821,429.97 in Stock - MarketBeat
Crinetics Pharmaceuticals Insider Sold Shares Worth $821,513, According to a Recent SEC Filing - marketscreener.com
Crinetics Pharmaceuticals (CRNX) COO sells 9,911 shares for RSU taxes - Stock Titan
Crinetics (NASDAQ: CRNX) CSO sells shares to cover RSU tax - Stock Titan
Crinetics (CRNX) CEO discloses tax-related share sales under 10b5-1 plan - Stock Titan
CRNX (NASDAQ: CRNX) insider sells shares via 10b5-1 and option exercise - Stock Titan
Jim Cramer on Crinetics: “That’s a better spec than Aquestive” - MSN
Finanzdaten der Crinetics Pharmaceuticals Inc-Aktie (CRNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Crinetics Pharmaceuticals Inc-Aktie (CRNX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Betz Stephen F. | Chief Scientific Officer |
Mar 16 '26 |
Sale |
37.37 |
10,612 |
396,610 |
137,101 |
| Struthers Richard Scott | President & CEO |
Mar 16 '26 |
Sale |
37.37 |
21,981 |
821,513 |
404,778 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):